Corticosteroid 0 14 0 14 B-treatment
therapy 15 22 15 22 I-treatment
( 23 24 23 24 O
> 24 25 24 25 O
10 25 27 25 27 B-lower_bound
mg 28 30 28 30 I-lower_bound
prednisone 31 41 31 41 O
/ 41 42 41 42 O
day 42 45 42 45 O
or 46 48 46 48 O
equivalent 49 59 49 59 O
) 59 60 59 60 O
within 61 67 61 67 O
1 68 69 68 69 B-upper_bound
week 70 74 70 74 I-upper_bound
prior 75 80 75 80 I-upper_bound
to 81 83 81 83 O
the 84 87 84 87 O
first 88 93 88 93 O
dose 94 98 94 98 O
of 99 101 99 101 O
study 102 107 102 107 O
drug 108 112 108 112 O

Dose 0 4 113 117 O
expansion 5 14 118 127 O
cohorts 15 22 128 135 O
: 22 23 135 136 O
Patients 24 32 137 145 O
with 33 37 146 150 O
histologically 38 52 151 165 O
or 53 55 166 168 O
cytologically 56 69 169 182 O
confirmed 70 79 183 192 O
diagnosis 80 89 193 202 O
of 90 92 203 205 O
1 93 94 206 207 O
of 95 97 208 210 O
specified 98 107 211 220 O
tumors 108 114 221 227 B-cancer
with 115 119 228 232 O
measurable 120 130 233 243 O
disease 131 138 244 251 O
per 139 142 252 255 O
RECIST 143 149 256 262 O
1.1 150 153 263 266 O
or 154 156 267 269 O
Lugano 157 163 270 276 O
criteria 164 172 277 285 O
. 172 173 285 286 O
Some 174 178 287 291 O
patients 179 187 292 300 O
may 188 191 301 304 O
have 192 196 305 309 O
been 197 201 310 314 O
previously 202 212 315 325 O
treated 213 220 326 333 O
with 221 225 334 338 O
a 226 227 339 340 O
PD-1 228 232 341 345 B-treatment
or 233 235 346 348 I-treatment
PD 236 238 349 351 I-treatment
- 238 239 351 352 I-treatment
L1 239 241 352 354 I-treatment
inhibitor 242 251 355 364 I-treatment

Eastern 0 7 365 372 B-clinical_variable
Cooperative 8 19 373 384 I-clinical_variable
Oncology 20 28 385 393 I-clinical_variable
Group 29 34 394 399 I-clinical_variable
performance 35 46 400 411 I-clinical_variable
status 47 53 412 418 I-clinical_variable
of 54 56 419 421 O
0 57 58 422 423 B-lower_bound
or 59 61 424 426 O
1 62 63 427 428 B-upper_bound

Myocardial 0 10 429 439 B-chronic_disease
infarction 11 21 440 450 I-chronic_disease
within 22 28 451 457 O
6 29 30 458 459 B-upper_bound
months 31 37 460 466 I-upper_bound

Prior 0 5 467 472 B-treatment
treatment 6 15 473 482 I-treatment
with 16 20 483 487 I-treatment
any 21 24 488 491 I-treatment
LAG-3 25 30 492 497 I-treatment
targeting 31 40 498 507 O
biologic 41 49 508 516 O
or 50 52 517 519 O
small 53 58 520 525 O
molecule 59 67 526 534 O

Radiation 0 9 535 544 B-treatment
therapy 10 17 545 552 I-treatment
within 18 24 553 559 O
2 25 26 560 561 B-upper_bound
weeks 27 32 562 567 I-upper_bound
prior 33 38 568 573 I-upper_bound
to 39 41 574 576 O
randomization 42 55 577 590 O
and 56 59 591 594 O
not 60 63 595 598 O
recovered 64 73 599 608 O
to 74 76 609 611 O
baseline 77 85 612 620 O
from 86 90 621 625 O
any 91 94 626 629 O
AE 95 97 630 632 O
due 98 101 633 636 O
to 102 104 637 639 O
radiation 105 114 640 649 O

Untreated 0 9 650 659 O
or 10 12 660 662 O
active 13 19 663 669 O
central 20 27 670 677 B-cancer
nervous 28 35 678 685 I-cancer
system 36 42 686 692 I-cancer
metastases 43 53 693 703 I-cancer
- 54 55 704 705 O
Ongoing 56 63 706 713 O
or 64 66 714 716 O
recent 67 73 717 723 O
( 74 75 724 725 O
within 75 81 725 731 O
5 82 83 732 733 B-upper_bound
years 84 89 734 739 I-upper_bound
) 89 90 739 740 O
evidence 91 99 741 749 O
of 100 102 750 752 O
significant 103 114 753 764 O
autoimmune 115 125 765 775 O
disease 126 133 776 783 O

